Short Interest in NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Declines By 71.2%

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPWGet Free Report) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 1,500 shares, a decrease of 71.2% from the October 15th total of 5,200 shares. Based on an average daily trading volume, of 3,400 shares, the short-interest ratio is presently 0.4 days.

NRx Pharmaceuticals Price Performance

NRXPW remained flat at $0.09 during midday trading on Tuesday. The stock has a fifty day moving average of $0.06 and a 200 day moving average of $0.07. NRx Pharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.39.

About NRx Pharmaceuticals

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

Recommended Stories

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.